Atossa Therapeutics Inc (ATOS) Stock Price, Quote & News

Company Profile

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 588 0256

Fax: 206 902 9658

Website: www.atossatherapeutics.com

Address:

107 Spring Street, Seattle, United States

NotLikeThis Jan. 8 at 2:24 AM

$ATOS sorry Doc that’s a NO Vote for me

0 · Reply

The_Real_Heisenberg Jan. 8 at 2:05 AM

$ATOS there is a small chance that vote fails. Quay will be forced to pump with no dillution. This is why this an options play. If that vote passes, youll lose a lot more than you will just getting some April calls for dirt cheap and seeing how it plays out. Because this is either worth a lot, or squat. Neither in between.

0 · Reply

Geezer54 Jan. 7 at 10:17 PM

$ATOS Thurs is usually PR day!

1 · Reply

Warrens__Buffet_ Jan. 7 at 8:01 PM

$ATOS where’s @JDAAT with his “who is buying they want retail shares should be .75 soon” comments 😭😭😭😂 or @NOYES with his “this will go crazy during power hour just wait” delusions 😭😭🤡🤡 The bulls on here kill me.. been right for 12 months no still haven’t been wrong.

1 · Reply

GooRich Jan. 7 at 6:04 PM

$ATOS it’s take time to consider to be bullish or bearish let’s check on them with few days or next week to be exact.

0 · Reply

Warrens__Buffet_ Jan. 7 at 5:43 PM

$ATOS why does this dude talk to Quay as if he’s on this board reading what you’re saying.. delusional bullls 🤡

1 · Reply

Kittyc803 Jan. 7 at 5:19 PM

$ATOS We are between 80-85% retail . If we voted no RS defeated easily . He will find another way . Do not let fear steal your shares . Hey Doc 👇 you have had plenty of time . Do not make the people who got you here suffer to enrich yourself . No matter where we trade approval is all that matters .

3 · Reply

BanannenBernhard Jan. 7 at 5:10 PM

$ATOS I would really like to know if we get a RS or not

3 · Reply

MAX2121 Jan. 7 at 4:56 PM

$ATOS let’s go guys double digits easy this month PT $12!

2 · Reply

zerotrust07 Jan. 7 at 4:24 PM

$ATOS Why cant there be a public service announcement when whoever pushed the stock up to 1.29. You know says..Hey we are going to inflate this and anyone that wants to get out this is the time before we rs and screw you. One can imagine ethical behavior.

1 · Reply

Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer

Dec 17, 2025, 8:15 AM EST - 21 days ago

Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category

Dec 15, 2025, 8:00 AM EST - 23 days ago

Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium

Dec 11, 2025, 8:00 AM EST - 27 days ago

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy

Dec 9, 2025, 8:00 AM EST - 4 weeks ago

Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen

Dec 4, 2025, 8:00 AM EST - 4 weeks ago

Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum

Dec 2, 2025, 8:00 AM EST - 5 weeks ago

Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma

Nov 17, 2025, 9:07 AM EST - 7 weeks ago

Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation

Nov 12, 2025, 8:15 AM EST - 2 months ago

Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Nov 6, 2025, 8:00 AM EST - 2 months ago

Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium

Oct 21, 2025, 8:00 AM EDT - 2 months ago

Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents

Oct 15, 2025, 8:00 AM EDT - 3 months ago

Atossa Therapeutics to Present at the Maxim Growth Summit 2025

Oct 14, 2025, 8:00 AM EDT - 3 months ago

Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness

Oct 13, 2025, 8:00 AM EDT - 3 months ago

Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals

Oct 6, 2025, 8:00 AM EDT - 3 months ago

Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities

Oct 1, 2025, 8:30 AM EDT - 3 months ago

Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones

Sep 17, 2025, 8:00 AM EDT - 4 months ago

Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services

Sep 8, 2025, 8:30 AM EDT - 4 months ago

Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction

Aug 28, 2025, 8:30 AM EDT - 4 months ago

Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference

Aug 20, 2025, 8:30 AM EDT - 5 months ago

Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer

Aug 12, 2025, 8:30 AM EDT - 5 months ago

Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update

Jul 29, 2025, 7:45 AM EDT - 5 months ago

Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer

Jun 2, 2025, 8:45 AM EDT - 7 months ago

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 9:00 AM EDT - 8 months ago

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22

May 14, 2025, 8:15 AM EDT - 8 months ago

Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen

May 13, 2025, 8:00 AM EDT - 8 months ago

Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

Apr 30, 2025, 8:45 AM EDT - 9 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

Apr 29, 2025, 8:45 AM EDT - 9 months ago

Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

Apr 22, 2025, 8:45 AM EDT - 9 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

Apr 10, 2025, 8:00 AM EDT - 9 months ago

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

Mar 25, 2025, 10:05 AM EDT - 10 months ago

Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 8:00 AM EDT - 10 months ago

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Mar 20, 2025, 9:13 AM EDT - 10 months ago

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Mar 11, 2025, 8:15 AM EDT - 10 months ago

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

Feb 5, 2025, 8:00 AM EST - 1 year ago

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

Jan 30, 2025, 8:17 AM EST - 1 year ago

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No.

Jan 23, 2025, 8:15 AM EST - 1 year ago

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

Dec 12, 2024, 8:15 AM EST - 1 year ago

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

Dec 11, 2024, 8:15 AM EST - 1 year ago

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

Dec 10, 2024, 9:05 AM EST - 1 year ago

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

Dec 9, 2024, 8:15 AM EST - 1 year ago

Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research

Nov 21, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

Nov 20, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

Nov 12, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 5, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

Nov 4, 2024, 6:30 AM EST - 1 year ago

Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:

Oct 31, 2024, 8:15 AM EDT - 1 year ago

Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

Oct 21, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer

Oct 14, 2024, 5:08 PM EDT - 1 year ago

Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit

Oct 1, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum

NotLikeThis Jan. 8 at 2:24 AM

$ATOS sorry Doc that’s a NO Vote for me

0 · Reply

The_Real_Heisenberg Jan. 8 at 2:05 AM

0 · Reply

Geezer54 Jan. 7 at 10:17 PM

$ATOS Thurs is usually PR day!

1 · Reply

Warrens__Buffet_ Jan. 7 at 8:01 PM

1 · Reply

GooRich Jan. 7 at 6:04 PM

$ATOS it’s take time to consider to be bullish or bearish let’s check on them with few days or next week to be exact.

0 · Reply

Warrens__Buffet_ Jan. 7 at 5:43 PM

$ATOS why does this dude talk to Quay as if he’s on this board reading what you’re saying.. delusional bullls 🤡

1 · Reply

Kittyc803 Jan. 7 at 5:19 PM

3 · Reply

BanannenBernhard Jan. 7 at 5:10 PM

$ATOS I would really like to know if we get a RS or not

3 · Reply

MAX2121 Jan. 7 at 4:56 PM

$ATOS let’s go guys double digits easy this month PT $12!

2 · Reply

zerotrust07 Jan. 7 at 4:24 PM

1 · Reply

AdamantiumBull Jan. 7 at 3:59 PM

$ATOS Oh thank goodness we have permission to proceed on another study. I was afraid we might run out of studies to do in 2026-2027. By the way, the reason he needs the rs is not just to get the price over $1. There will be another cash raise very soon to pay for all the new studies. Feel free to bookmark this and reshare to tell me I was right once it happens.

1 · Reply

CJ27969 Jan. 7 at 3:45 PM

$ATOS want to put your money where your mouth is? RS will be approved easily.

1 · Reply

stas_stazz Jan. 7 at 3:33 PM

$ATOS Everyone should be voting NO ! Let Quay do it organically like he said so himself! He has been dragging this out for 5 years now and meanwhile making 2M per year..he should put his wallet where his mouth been yapping. He should be paying for wasting everyone’s time on Covid tweets, nasal sprays fiasco and fumbling with appropriate dosage’s. He has the funds to buy the stock and show everyone that he believes in his own dam company!

3 · Reply